English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: The development of a novel biological marker for diagnosis and prognosis prediction of epithelial ovarian cancer (EOC) remains urgent. Current literature shows that microRNA-21 (miRNA-21/miR-21) are involved in the growth, metastasis, and apoptosis of cancer cells. This study aims to determine the difference in miR-21 expression between stages, histopathology type, and residual tumor after surgery in EOC patients. Methods: A cross sectional study was conducted among 40 EOC patients. Blood samples were taken prior to surgery, and when the pathological anatomy result confirmed the presence of EOC, the RNA was then isolated. Based on the RNA, the cDNA was synthesized and run through qPCR. All data were analyzed using the GenEx analyzing software. Results: The expression of miR-21 in the advanced stage was 1.36 up-fold compared to the early stage (p=0.52). The expression of miR-21 in type II EOC was 1.33 up-fold compared to type I EOC (p=0.56). The expression of miR-21 in residual tumor >1cm after surgery was 1.30 up-fold compare to residual tumor after surgery

The role of circulating MicroRNA-21 (miR-21) in epithelial ovarian cancer